Blurbs

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioNTech SE (BNTX) and Aptose Biosciences (APTO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BioNTech SE (BNTXResearch Report) and Aptose Biosciences (APTOResearch Report).

BioNTech SE (BNTX)

In a report issued on June 1, Emmanuel Papadakis from Deutsche Bank maintained a Hold rating on BioNTech SE, with a price target of $180.00. The company’s shares closed last Friday at $143.85, close to its 52-week low of $121.32.

According to TipRanks.com, Papadakis is a 3-star analyst with an average return of 1.7% and a 49.3% success rate. Papadakis covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Novo Nordisk, and Moderna.

Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $236.40, implying a 59.5% upside from current levels. In a report issued on May 17, UBS also maintained a Hold rating on the stock with a $168.00 price target.

See today’s best-performing stocks on TipRanks >>

Aptose Biosciences (APTO)

RBC Capital analyst Gregory Renza maintained a Buy rating on Aptose Biosciences on June 2 and set a price target of $6.00. The company’s shares closed last Friday at $0.87, close to its 52-week low of $0.84.

According to TipRanks.com, Renza has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -9.9% and a 28.2% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Aptose Biosciences is a Strong Buy with an average price target of $7.98, representing a 772.3% upside. In a report issued on June 3, H.C. Wainwright also maintained a Buy rating on the stock with a $12.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed